Alexa

50 Most Valuable Brands of the Year 2020

GreenLight Biosciences, Inc. – The sign of a better and healthier future

thesiliconreview-dr-andrey-j-zarur-ceo-greenlight-biosciences-Inc.jpg

Cell-free RNA synthesis is becoming increasingly used for protein production as yields increase and costs decrease. Advances in reconstituted CFRS systems such as the Protein synthesis Using Recombinant Elements (PURE) system offer new opportunities to tailor the reactions for specialized applications including in vitro protein evolution, protein microarrays, isotopic labeling, and incorporating unnatural amino acids. In this study, using firefly luciferase synthesis as a reporter system, the firm has improved PURE system productivity up to 5 fold by adding or adjusting a variety of factors that affect transcription and translation, including Elongation factors, ribosome recycling factor (RRF), release factors, chaperones BSA, and tRNAs. The work provides a more efficient defined in vitro transcription and translation system and a deeper understanding of the factors that limit the whole system efficiency. These systems provide the ability to produce a variety of compounds and present numerous advantages: concentrations of some system components can be controlled; therefore a large parameter space can be studied

GreenLight Bioscience, Inc. is one such firm that is dedicated to bringing cell-free RNA production process to market. The firm will work to lead more sustainable global development, and it promises to deliver a safe solution without compromising the Earth and its people. The company has pioneered a groundbreaking technology to create high-performing, natural RNA products to address global sustainability challenges and promote healthier plants, foods, and people. It also opened a biological platform to partners in academia and industry, to help them research and create RNA-based products that can preserve their natural resources and protect the environment for future generations.

Why GreenLight Biosciences

Fulfilling demand through advanced biology

Multi-billion-dollar corporations and innovative startups are starting to recognize the role of messenger RNA (mRNA) plays in improving human health and stopping the spread of infectious disease. The company's end-to-end, self-contained mRNA platform enables the fast, scalable, robust, and cost-efficient production of mRNA vaccines and antibody therapies.

Solving the mRNA Challenge the GreenLight Way

Manufacturing and delivery of quality RNA for vaccines and antibodies has historically been an issue to unlocking the potential of the nucleic acid to control the synthesis of proteins. Creating quality RNA is expensive to do in laboratories. Doing so also takes a lot of time, making production difficult to scale.  The company's mRNA biomanufacturing platform aims to create quality mRNA quickly. An end-to-end, self-contained process enables the cost-efficient production of mRNA vaccines and antibody therapies when compared to traditional production processes.

RNA for Human Health

The firm is investing in internal programs and intensifying collaborations with universities, foundations, and industry partners to deploy its mRNA production process to Human Health applications. Their platform:

  • Eliminates existing constraints in producing mRNA clinical materials
  • Enables cost and kilogram-scale production for commercial mRNA products
  • Delivers speed to the market, quality, and cost for mRNA vaccines and antibody therapies

Complex science

GreenLight's proprietary mRNA manufacturing prototype is a cost-effective, high-quality option to enable the development of applications and solutions for vaccines and therapies. Along with their university partners, the firm has produced numerous mRNA samples expressing reporter genes and vaccines for testing in mice. Studies show equivalent quality between GreenLight mRNA compared to alternative state-of-the-art production methods. Besides, the speed of production is faster, and the cost is lower than the current mRNA manufacturing methods.

RNA: a targeted, natural solution for plant and life sciences

In agriculture, RNA works without affecting the DNA of the targeted pest, while also protecting the plant. In life sciences, RNA can create more effective vaccines and antibody therapies faster than is currently possible.

GreenLight's key opportunities include the development of:

Double-stranded RNAs (dsRNAs) in agriculture to allow for targeted biocontrol of pests including insects, weeds, and fungi — in a highly targeted, environmentally friendly manner

Messenger RNAs (mRNAs) in healthcare to create highly effective vaccines to control infectious disease

Small interfering RNAs (siRNAs) in life sciences to stop the disease in humans and animals

The pre-eminent leader behind the success of GreenLight Biosciences, Inc.

Dr. Andrey J. Zarur is the Co-Founder, President, and also serves as the Chief Executive Officer of GreenLight Biosciences, Inc.  He has been active in early-stage life sciences companies for over 20 years and has actively participated in the creation, IPO, and M&A of over a dozen companies in the healthcare and clean energy sectors. Before starting GreenLight, Dr. Andrey was Managing Partner at Kodiak Venture Partners, an early-stage, technology-driven venture fund based in Boston. He holds a master's and a Ph.D. in chemical engineering from the Massachusetts Institute of Technology and undergraduate degrees from the National University of Mexico. Dr. Andrey is the author of several peer-reviewed articles and holds over 100 provisional and issued patents.

"Our work will lead to more sustainable global development, and we promise to deliver our safe solution without compromising the Earth and its people."